INFORMATIONAL PURPOSES ONLY. Not medical, legal, or travel advice. Verify with official sources before acting. See corrections log.
Right to try laws and requirements in Montana. Citations, verification dates, and source links for every data point.
| Dimension | Value | Citation | Source | Verified | Confidence |
|---|---|---|---|---|---|
| Have Enacted State Right to Try Laws | have state RTT laws | Mont. Code Ann. §§ 50-12-101 to 50-12-110 (Right to Try Act)“"Experimental treatment" means the provision of a medical intervention by a health care provider involving an investigational drug, biological product, device, or other treatment that has successfully completed phase 1 of a clinical trial” | Link | 2026-10-09 | high |
| Enacted Right to Try Laws Before Federal Law | 2015 | Mont. Laws 2015, ch. 135“En. Sec. 1, Ch. 135, L. 2015.”Note: Enacted 2015 (Ch. 135, L. 2015), not 2017. RAPS's June 2015 tracker also listed Montana as 'Signed Into Law'. | Link | 2026-10-09 | high |
| Require Individualized Manufacturer Approval for RTT | do not require individualized approval sources differ | Mont. Code Ann. §§ 50-12-102, 50-12-104 (as amended by Ch. 413, L. 2023; Ch. 621, L. 2025)“A patient is eligible for an experimental treatment if the patient has: (1) evaluated other treatment options currently approved by the United States food and drug administration”Note: Montana is on the brief's lead list of RTT 2.0 states. In 2023 (SB 422, Ch. 413) it broadened its RTT Act to non-terminal patients, and in 2025 (Ch. 621) it added experimental treatment centers. But the current MCA Title 50 ch. 12 part 1 (101-110) contains no 'individualized investigational treatment' definition or patient-specific (genetic-profile) pathway. 'Experimental treatment' still requires completion of phase 1. Part 2 is palliative care. So Montana's law does not match the Goldwater individualized-treatment model (best value FALSE), although trackers may count the 2023 expansion as RTT 2.0. Stored TRUE kept as a possible alternative; needs human review. | Link | 2026-10-09 | medium |
| Provide Manufacturer Liability Protection Under RTT | provide liability shield | Mont. Code Ann. § 50-12-110“A manufacturer of an investigational drug, biological product, or device, a pharmacist, a health care facility, a health care provider, or a person or entity involved in the care of a patient” | Link | 2026-10-09 | high |
| Require Insurer Coverage of Investigational Treatments | do not require coverage | Mont. Code Ann. § 50-12-106“A health plan, third-party administrator, or governmental agency may provide coverage for the cost of an experimental treatment or the cost of services related to the provision of an experimental treatment under this part.” | Link | 2026-10-09 | high |
View full Montana profile (all layers) · Report an error on this page